Dear Madam / Sir,
a new therapeutic approach is being tested in patients with midgut carcinoid tumor.
This website provides summary information on an international clinical study (NETTER-1 study) involving Nuclear Medicine Centers in Europe and the USA, to verify the efficacy and safety of the investigational therapy (177Lu-DOTA0-Tyr3-Octreotate) in comparison with an already assessed treatment (Octreotide LAR).
Title of the study:
A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors.